What Is 17β-Hydroxysteroid dehydrogenase

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 14, 2026

Quick Answer: 17β-Hydroxysteroid dehydrogenase (17β-HSD) is an enzyme family involved in steroid hormone metabolism, specifically regulating active sex hormones like testosterone and estradiol. There are at least 14 known isoforms, with 17β-HSD type 3 playing a key role in testosterone biosynthesis in the testes.

Key Facts

17β-HSD includes at least 14 human isoforms identified as of 2023
17β-HSD type 3 is encoded by the HSD17B3 gene on chromosome 9q22
Deficiency in 17β-HSD3 causes male pseudohermaphroditism in 1 in 147,000 male births
17β-HSD enzymes regulate estradiol levels, impacting breast cancer progression
Type 17β-HSD1 is overexpressed in 85% of endometriosis lesions

Overview

17β-Hydroxysteroid dehydrogenase (17β-HSD) is a family of enzymes responsible for catalyzing the reduction or oxidation of steroid hormones at the C17 position. These enzymes play a pivotal role in regulating the biological activity of sex steroids such as testosterone, estradiol, and dihydrotestosterone.

By converting weak or inactive steroids into their potent forms—or vice versa—17β-HSD enzymes help maintain hormonal balance across tissues. Their activity is crucial in reproductive organs, adrenal glands, liver, and adipose tissue, influencing development, fertility, and disease processes.

17β-HSD comprises at least 14 distinct isoforms in humans, each encoded by different genes and exhibiting tissue-specific expression patterns as of 2023.
The enzyme regulates the conversion of androstenedione to testosterone, a reaction primarily driven by 17β-HSD type 3 in the testes.
17β-HSD type 1 is highly active in the ovaries and placenta, where it reduces estrone to the more potent estradiol during pregnancy.
Mutations in HSD17B3 gene cause 17β-HSD3 deficiency, leading to disorders of sex development (DSD) with an incidence of approximately 1 in 147,000 male births.
Several isoforms, including types 7 and 12, are implicated in intracrine steroid metabolism, allowing cells to locally activate or deactivate hormones.

How It Works

The function of 17β-HSD enzymes depends on their isoform, cofactor preference (NADH vs. NADPH), and subcellular localization. These enzymes catalyze reversible reactions, either activating or inactivating sex hormones based on physiological needs.

Reduction Reaction:17β-HSD1 uses NADPH to convert estrone (E1) into the biologically active estradiol (E2), enhancing estrogenic effects in target tissues.
Oxidation Reaction:17β-HSD2 oxidizes estradiol back to estrone using NAD⁺, reducing estrogenic activity in tissues like the endometrium and placenta.
Tissue Specificity:17β-HSD3 is expressed almost exclusively in the testes and adrenal glands, where it supports testosterone synthesis during fetal development.
Cofactor Dependence: Type 5 (HSD17B5) prefers NADH and is involved in androgen activation in prostate and adipose tissue.
Enzyme Kinetics:17β-HSD7 has a low Km for estrone, making it highly efficient in local estrogen production within brain and breast tissues.
Reversibility: Many isoforms, such as 17β-HSD10, exhibit bidirectional activity, allowing dynamic regulation of hormone levels in response to metabolic signals.

Key Comparison

Isoform	Gene	Primary Function	Tissue Expression	Cofactor
17β-HSD1	HSD17B1	Reduces estrone to estradiol	Ovaries, placenta, breast	NADPH
17β-HSD2	HSD17B2	Oxidizes estradiol to estrone	Endometrium, liver, kidney	NAD⁺
17β-HSD3	HSD17B3	Converts androstenedione to testosterone	Testes, adrenal glands	NADPH
17β-HSD5	AKR1C3	Activates androgens and estrogens	Prostate, adrenal, adipose	NADH
17β-HSD10	HSD17B10	Binds neurosteroids and regulates metabolism	Brain, heart, mitochondria	NAD⁺

This comparison highlights the functional diversity of 17β-HSD isoforms. While some enhance hormone activity, others inactivate it, allowing precise control over steroid signaling in different tissues. These differences are critical for understanding hormone-dependent diseases and developing targeted therapies.

Key Facts

Research into 17β-HSD enzymes has revealed their significance in endocrinology, oncology, and reproductive medicine. Their roles in hormone-dependent conditions make them key targets for diagnostics and treatment.

14 human isoforms have been identified as of 2023, each with unique substrate specificity and tissue distribution, influencing clinical outcomes differently.
HSD17B3 gene is located on chromosome 9q22, and over 90 mutations have been linked to 17β-HSD3 deficiency, a rare autosomal recessive disorder.
17β-HSD1 is overexpressed in 85% of endometriosis lesions, contributing to local estrogen production and disease progression.
In breast cancer, 17β-HSD5 expression correlates with tumor aggressiveness and poor prognosis in 60% of estrogen receptor-negative cases.
17β-HSD10 is associated with Alzheimer’s disease, with studies showing 30–40% higher expression in affected brain regions.
Pharmacological inhibitors targeting 17β-HSD1 are in Phase II trials for endometriosis, showing 50% reduction in lesion size in animal models.

Why It Matters

Understanding 17β-Hydroxysteroid dehydrogenase is essential for diagnosing and treating hormonal disorders, cancers, and developmental conditions. Its isoforms serve as biomarkers and therapeutic targets, influencing modern endocrinology.

Defects in 17β-HSD3 lead to undervirilization in genetic males, often diagnosed at birth with a prevalence of 1 in 147,000 live births.
Inhibitors of 17β-HSD1 may offer non-hormonal treatments for endometriosis, reducing reliance on estrogen-suppressing drugs with severe side effects.
17β-HSD2 downregulation in colorectal cancer is linked to increased local estradiol, promoting tumor growth in postmenopausal women.
Targeting 17β-HSD5 in prostate cancer could reduce intratumoral androgen synthesis, improving outcomes in castration-resistant cases.
Genetic screening for HSD17B mutations is becoming standard in pediatric endocrinology for early diagnosis of disorders of sex development.

As research advances, the 17β-HSD enzyme family continues to emerge as a cornerstone in precision medicine, offering pathways for personalized treatment of hormone-sensitive conditions.